Back Login for AI Analysis

    DMAC (STOCKS)

    DiaMedica Therapeutics Inc. Common Stock

    $6.300000
    +0.310000 (+5.18%)
    Prev close: $5.990000
    Company Information
    Exchange
    XNAS
    Sector
    Health Technology
    Industry
    Biotechnology
    CEO
    Rick John Pauls
    Asset Type
    stocks
    Website
    Visit
    Fundamentals
    Market Cap
    $338.38M
    Employees
    28
    P/E (TTM)
    -8.58
    P/B (TTM)
    5.74
    Dividend Yield
    Technical Indicators
    SMA 10
    SMA 20
    SMA 50
    EMA 9
    EMA 21
    RSI
    MACD State
    Recent News

    No recent news found for this ticker.

    Financial Statements
    TTM (Dec 2025)
    Revenues $0.00
    Nonoperating Income/Loss $1.66M
    Operating Expenses $34.40M
    Research and Development $24.61M
    Other Operating Expenses $9.78M
    Operating Income/Loss -$34.40M
    Income/Loss From Continuing Operations After Tax -$32.77M
    Income/Loss From Continuing Operations Before Tax -$32.74M
    Income Tax Expense/Benefit $28.00K
    Income Tax Expense/Benefit, Current $28.00K
    Income Tax Expense/Benefit, Deferred $0.00
    Net Income/Loss -$32.77M
    Net Income/Loss Attributable To Noncontrolling Interest $0.00
    Net Income/Loss Attributable To Parent -$32.77M
    Net Income/Loss Available To Common Stockholders, Basic -$32.77M
    Participating Securities, Distributed And Undistributed Earnings/Loss, Basic $0.00
    Preferred Stock Dividends And Other Adjustments $0.00
    Basic Earnings Per Share -$0.70
    Basic Average Shares 46,980,777
    Assets $61.37M
    Current Assets $60.63M
    Cash $59.90M
    Other Current Assets $729.00K
    Noncurrent Assets $742.00K
    Fixed Assets $145.00K
    Other Non-current Assets $597.00K
    Liabilities $5.26M
    Current Liabilities $5.13M
    Accounts Payable $1.48M
    Wages $1.38M
    Other Current Liabilities $2.28M
    Noncurrent Liabilities $128.00K
    Equity $56.11M
    Equity Attributable To Noncontrolling Interest $0.00
    Equity Attributable To Parent $56.11M
    Liabilities And Equity $61.37M
    Net Cash Flow From Operating Activities -$29.06M
    Net Cash Flow From Operating Activities, Continuing -$29.06M
    Net Cash Flow From Investing Activities -$2.19M
    Net Cash Flow From Investing Activities, Continuing -$2.19M
    Net Cash Flow From Financing Activities $43.88M
    Net Cash Flow From Financing Activities, Continuing $43.88M
    Net Cash Flow $12.62M
    Net Cash Flow, Continuing $12.62M
    Comprehensive Income/Loss -$32.74M
    Comprehensive Income/Loss Attributable To Noncontrolling Interest $0.00
    Comprehensive Income/Loss Attributable To Parent -$32.74M
    Other Comprehensive Income/Loss -$32.74M